drugset / Trial / NCT03639181
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
NaSingle-groupOpen-labelTreatment
Summary
An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)
Timeline
- Start
- 2018-10-15
- Primary completion
- 2021-09
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APL-501 | Monoclonal antibody | 3 mg/kg | Intravenous |